Calcific uremic arteriolopathy: pathophysiology, reactive oxygen species and therapeutic approaches
- PMID: 20716935
- PMCID: PMC2952095
- DOI: 10.4161/oxim.3.2.11354
Calcific uremic arteriolopathy: pathophysiology, reactive oxygen species and therapeutic approaches
Abstract
Calcific uremic arteriolopathy (CUA)/calciphylaxis is an important cause of morbidity and mortality in patients with chronic kidney disease requiring renal replacement. Once thought to be rare, it is being increasingly recognized and reported on a global scale. The uremic milieu predisposes to multiple metabolic toxicities including increased levels of reactive oxygen species and inflammation. Increased oxidative stress and inflammation promote this arteriolopathy by adversely affecting endothelial function resulting in a prothrombotic milieu and significant remodeling effects on vascular smooth muscle cells. These arteriolar pathological effects include intimal hyperplasia, inflammation, endovascular fibrosis and vascular smooth muscle cell apoptosis and differentiation into bone forming osteoblast-like cells resulting in medial calcification. Systemic factors promoting this vascular condition include elevated calcium, parathyroid hormone, and hyperphosphatemia with consequent increases in the calcium x phosphate product. The uremic milieu contributes to a marked increased in upstream reactive oxygen species - oxidative stress and subsequent downstream increased inflammation, in part, via activation of the nuclear transcription factor NFkappaB and associated downstream cytokine pathways. Consitutive anti-calcification proteins such as Fetuin-A and matrix GLA proteins and their signaling pathways may be decreased, which further contributes to medial vascular calcification. The resulting clinical entity is painful, debilitating and contributes to the excess morbidity and mortality associated with chronic kidney disease and end stage renal disease. These same histopathologic conditions also occur in patients without uremia and therefore, the term calcific obliterative arteriolopathy could be utilized in these conditions.
Figures








Similar articles
-
Questionable specificity of histologic findings in calcific uremic arteriolopathy.Kidney Int. 2018 Aug;94(2):390-395. doi: 10.1016/j.kint.2018.03.016. Epub 2018 Jun 7. Kidney Int. 2018. PMID: 29885932
-
Calcific uremic arteriolopathy: advances in pathogenesis and treatment.Semin Dial. 2007 Mar-Apr;20(2):150-7. doi: 10.1111/j.1525-139X.2007.00263.x. Semin Dial. 2007. PMID: 17374090 Review.
-
Cutaneous necrosis from calcific uremic arteriolopathy.Am J Kidney Dis. 1998 Sep;32(3):384-91. doi: 10.1053/ajkd.1998.v32.pm9740153. Am J Kidney Dis. 1998. PMID: 9740153 Review.
-
Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate.Cardiovasc Diabetol. 2005 Mar 18;4:4. doi: 10.1186/1475-2840-4-4. Cardiovasc Diabetol. 2005. PMID: 15777477 Free PMC article. Review.
-
Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathy.Nephrol Dial Transplant. 2013 Apr;28(4):856-68. doi: 10.1093/ndt/gfs466. Epub 2012 Dec 6. Nephrol Dial Transplant. 2013. PMID: 23223222
Cited by
-
Chronic Kidney Disease and Calciphylaxis: A Literature Review.Cureus. 2018 Sep 19;10(9):e3334. doi: 10.7759/cureus.3334. Cureus. 2018. PMID: 30473967 Free PMC article. Review.
-
Multifactorial aetiology for non-uremic calciphylaxis: a case report.J Community Hosp Intern Med Perspect. 2018 Jun 12;8(3):163-166. doi: 10.1080/20009666.2018.1479617. eCollection 2018. J Community Hosp Intern Med Perspect. 2018. PMID: 29915661 Free PMC article.
-
Cardiorenal metabolic syndrome and diabetic cognopathy.Cardiorenal Med. 2013 Dec;3(4):265-82. doi: 10.1159/000357113. Epub 2013 Nov 29. Cardiorenal Med. 2013. PMID: 24474955 Free PMC article.
-
Warfarin-Induced Calciphylaxis in a COVID-19 Patient.Cureus. 2020 Dec 24;12(12):e12249. doi: 10.7759/cureus.12249. Cureus. 2020. PMID: 33391959 Free PMC article.
-
Calciphylaxis: A Rare Manifestation of a Common Disease.Cureus. 2025 May 21;17(5):e84550. doi: 10.7759/cureus.84550. eCollection 2025 May. Cureus. 2025. PMID: 40546520 Free PMC article.
References
-
- Coates T, Kirkland GS, Dymock RB, Murphy BF, Brealey JK, Mathew TH, et al. Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis. 1998;32:384–391. - PubMed
-
- Pollock B, Cunliffe W, Merchant W. Calciphylaxis in the absence of renal failure. Clin Exp Dermatol. 2000;25:389. - PubMed
-
- Goyal S, Huhn K, Provost T. Calciphylaxis in a patient without renal failure or elevated parathyroid hormone: the possible aetiological role of chemotherapy. Br J Dermatol. 2000;143:1087–1090. - PubMed
-
- Don BR, Chin AL. A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies. Clin Nephrol. 2003;59:463–470. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources